Dexamethasone is a medication used in this trial to help reduce inflammation in the body. It is a type of steroid that can help improve breathing and reduce the severity of symptoms in patients with severe respiratory issues, such as those caused by COVID-19.

Tocilizumab is an immunosuppressive drug that is used to treat severe inflammation. In the context of this trial, it is being tested to see if it can help reduce the immune system’s overreaction in patients with severe COVID-19, potentially improving their outcomes.

Baricitinib is a medication that works by interfering with the activity of certain enzymes in the body that are involved in inflammation. It is being studied in this trial to determine if it can help reduce the severity of COVID-19 symptoms by modulating the immune response.

Regeneron is a combination of monoclonal antibodies designed to target the coronavirus. This therapy aims to help the immune system fight off the virus more effectively, potentially reducing the severity and duration of the illness in patients with COVID-19.

Convalescent Plasma is a therapy that involves using blood plasma from people who have recovered from COVID-19. The plasma contains antibodies that may help patients currently fighting the virus by boosting their immune response.

Pneumonia – Pneumonia is an infection that inflames the air sacs in one or both lungs, which may fill with fluid or pus. This condition can cause symptoms such as cough, fever, chills, and difficulty breathing. It can be caused by a variety of organisms, including bacteria, viruses, and fungi. The disease can range from mild to severe, depending on factors like the type of germ causing the infection and the individual’s age and overall health. As the infection progresses, it can lead to complications such as pleurisy, lung abscesses, or acute respiratory distress syndrome. Recovery time can vary, with some individuals experiencing prolonged fatigue and weakness even after the infection has cleared.